Tab Adult, adolescent & childn from 3 mth at least 25 kg 300 mg bd or 600 mg once daily. Childn ≥20 kg to <25 kg ½ tab in the morning & 1 tab in the evening, 14 to <20 kg ½ tab bd. Oral solnAdult, adolescent & childn at least 25 kg 15 mL bd or 30 mL once daily. Childn <14 kg 8 mg/kg bd or 16 mg/kg once daily, up to max: 300 mg bd or 600 mg once daily. Mild hepatic impairment (Child-Pugh score 5-6) 200 mg (10 mL) bd.
Hypersensitivity. Discontinue use in patients w/ HLA-B* 5701 allele or if HSR is suspected. Lactic acidosis & severe hepatomegaly w/ steatosis. Immune reconstitution syndrome; MI. Opportunistic infections & other complications of HIV infection. Manage serum lipids & blood glucose. Known risk factors for liver disease. Avoid in patients w/ ESRD. Pregnancy & lactation. Mitochondrial dysfunction in neonates & infants exposed in utero or peri-partum to NRTIs. Childn <3 mth. Oral soln:Hereditary fructose intolerance.
J05AF06 - abacavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
